Camila Bonemann Bender

Universidade Federal de Pelotas

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Tiago Collares

Universidade Federal de Pelotas

Fabiana K. Seixas

Universidade Federal de Pelotas

Noah Robertson

University of South Carolina

Luke R. Jordan

University of Illinois Chicago

Kyle M. Schachtschneider

University of Illinois Chicago

Lawrence B. Schook

University of Illinois Urbana-Champaign

Courtni R. Bolt

University of Illinois Urbana-Champaign

Natália Vieira Segatto

Universidade Federal de Pelotas

Kamila Grokoski

Hospital de Clínicas de Porto Alegre

Aisha Qazi

University of Illinois Urbana-Champaign

Cooperative Institutions

Universidade Federal do Rio Grande do Sul

Universidade Federal de Pelotas

Universidade Federal de Santa Maria

University of Illinois Urbana-Champaign

Hospital de Clínicas de Porto Alegre

Universidade Federal de Ciências da Saúde de Porto Alegre

University of Illinois Chicago

Universidade Federal de Santa Catarina

Universidade de São Paulo

Universidade Federal do Rio Grande

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Protective effects of octylseleno-xylofuranoside in a streptozotocin-induced mouse model of Alzheimer's disease

European Journal of Pharmacology (2021)

Rodolfo Baldinotti Mariana G. Fronza Jenifer Fetter Luana Aparecida Alves da Silva Camila Bonemann Bender

10.1016/j.ejphar.2021.174499

Cite

Citations (4)

Perspective: Humanized Pig Models of Bladder Cancer

Frontiers in Molecular Biosciences (2021)

Natália Vieira Segatto Camila Bonemann Bender Fabiana K. Seixas Kyle M. Schachtschneider Lawrence B. Schook

Bladder cancer (BC) is the 10th most common neoplasia worldwide and holds expensive treatment costs due to its high recurrence rates, resistance to therapy and the need for lifelong surveillance. Thus, it is necessary to improve the current therapy options and identify more effective treatments for BC. Biological models capable of recapitulating the characteristics of human BC pathology are essential in evaluating the effectiveness of new therapies. Currently, the most commonly used BC models are experimentally induced murine models and spontaneous canine models, which are either insufficient due to their small size and inability to translate results to clinical basis (murine models) or rarely spontaneously observed BC (canine models). Pigs represent a potentially useful animal for the development of personalized tumors due to their size, anatomy, physiology, metabolism, immunity, and genetics similar to humans and the ability to experimentally induce tumors. Pigs have emerged as suitable biomedical models for several human diseases. In this sense, the present perspective focuses on the genetic basis for BC; presents current BC animal models available along with their limitations; and proposes the pig as an adequate animal to develop humanized large animal models of BC. Genetic alterations commonly found in human BC can be explored to create genetically defined porcine models, including the BC driver mutations observed in the FGFR3, PIK3CA, PTEN, RB1, HRAS, and TP53 genes. The development of such robust models for BC has great value in the study of pathology and the screening of new therapeutic and diagnostic approaches to the disease.

HRAS

Humanized mouse

Animal model

Preclinical testing

genetic model

10.3389/fmolb.2021.681044

Cite

Citations (2)

What Happens to Refractory or Intolerant Chronic Myeloid Leukemia Patients without Access to Clinical Trials?

Clinical Lymphoma Myeloma & Leukemia (2017)

Guilherme Rasia Bosi Laura Fogliatto Mariana Pinto Pereira Tito Vanelli Costa Kamila Grokoski

Refractory (planetary science)

10.1016/j.clml.2017.07.120

Cite

Citations (0)

Oncopig bladder cancer cells recapitulate human bladder cancer treatment responses in vitro

Frontiers in Oncology (2024)

Natália Vieira Segatto Lucas D. Simões Camila Bonemann Bender Fernanda S. de Sousa Thaís Larré Oliveira

Introduction Bladder cancer is a common neoplasia of the urinary tract that holds the highest cost of lifelong treatment per patient, highlighting the need for a continuous search for new therapies for the disease. Current bladder cancer models are either imperfect in their ability to translate results to clinical practice (mouse models), or rare and not inducible (canine models). Swine models are an attractive alternative to model the disease due to their similarities with humans on several levels. The Oncopig Cancer Model has been shown to develop tumors that closely resemble human tumors. However, urothelial carcinoma has not yet been studied in this platform. Methods We aimed to develop novel Oncopig bladder cancer cell line (BCCL) and investigate whether these urothelial swine cells mimic human bladder cancer cell line (5637 and T24) treatment-responses to cisplatin, doxorubicin, and gemcitabine in vitro. Results Results demonstrated consistent treatment responses between Oncopig and human cells in most concentrations tested (p>0.05). Overall, Oncopig cells were more predictive of T24 than 5637 cell therapeutic responses. Microarray analysis also demonstrated similar alterations in expression of apoptotic (GADD45B and TP53INP1) and cytoskeleton-related genes (ZMYM6 and RND1) following gemcitabine exposure between 5637 (human) and Oncopig BCCL cells, indicating apoptosis may be triggered through similar signaling pathways. Molecular docking results indicated that swine and humans had similar Dg values between the chemotherapeutics and their target proteins. Discussion Taken together, these results suggest the Oncopig could be an attractive animal to model urothelial carcinoma due to similarities in in vitro therapeutic responses compared to human cells.

10.3389/fonc.2024.1323422

Cite

Citations (1)

Synthesis and Antitumoral Lung Carcinoma A549 and Antioxidant Activity Assays Of New Chiral β‐Aryl‐Chalcogenium Azide Compounds

ChemistrySelect (2017)

Greice Tabarelli Luciano Dornelles Bernardo A. Iglesias Débora Farina Gonçalves Sílvio Terra Stefanello

Abstract The synthesis of chiral azido organochalcogenium compounds prepared from inexpensive and commerciallyavailable α‐amino alcohols through diazo transfer reaction are disclosed. The products were obtained in good yields in a modulate synthetic route, affording an efficient methodology for preparing new chiral β‐aryl‐chalcogenium azide compounds. These compounds were evaluated for in vitro antitumoral lung carcinoma A549 as well as electrochemical and antioxidant assays. They presented prominent activities of apoptosis and cell cycle arrest induction as well as antioxidant properties. Additionally, the toxicities in vivo for the most effective compounds were evaluated and no overt sign of toxicity was observed.

10.1002/slct.201701107

Cite

Citations (8)

Nano-BCG: A Promising Delivery System for Treatment of Human Bladder Cancer

Frontiers in Pharmacology (2018)

Julieti H. Buss Karine R. Begnini Camila Bonemann Bender Adriana Raffin Pohlmann Sı́lvia Stanisçuaski Guterres

Mycobacterium bovis bacillus Calmette–Guerin (BCG) remains at the forefront of immunotherapy for treating bladder cancer patients. However, the incidence of recurrence and progression to invasive cancer is commonly observed. There are no established effective intravesical therapies available for patients, whose tumors recur following BCG treatment, representing an important unmet clinical need. In addition, there are very limited options for patients who do not respond to or tolerate chemotherapy due to toxicities, resulting in poor overall treatment outcomes. Within this context, nanotechnology is an emergent and promising tool for: (1) controlling drug release for extended time frames, (2) combination therapies due to the ability to encapsulate multiple drugs simultaneously, (3) reducing systemic side effects, (4) increasing bioavailability, (5) and increasing the viability of various routes of administration. Moreover, bladder cancer is often characterized by high mutation rates and over expression of tumor antigens on the tumor cell surface. Therapeutic targeting of these biomolecules may be improved by nanotechnology strategies. In this mini-review, we discuss how nanotechnology can help overcome current obstacles in bladder cancer treatment, and how nanotechnology can facilitate combination chemotherapeutic and BCG immunotherapies for the treatment of nonmuscle invasive urothelial bladder cancer.

Cancer Immunotherapy

10.3389/fphar.2017.00977

Cite

Citations (20)

Myeloid Differentiation Factor 88 (MYD88) Gene Mutation in Diffuse Large B-Cell Lymphomas: Should it be Included in Routine?

Clinical Lymphoma Myeloma & Leukemia (2017)

Laura Fogliatto Marines Bizarro Barra Yuri Machado Strey Paula Prieto Oliveira Israel Bendit

10.1016/j.clml.2017.07.216

Cite

Citations (0)